Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 7/20 | 0.35 |
| ▸ | RAB9A | P51151 | 7/20 | 0.35 |
| ▸ | HTT | P42858 | 6/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | GALR3 | O60755 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27544368 | 1.00 | TBXAS1 (0.44) | TBXAS1TLR8NPC1RAB9AHTT | |
| SCHEMBL1277116 | 0.98 | TBXAS1 (0.41) | TBXAS1TLR8NPC1RAB9AHTT | |
| SCHEMBL1277074 | 0.92 | — | — | |
| SCHEMBL9481880 | 0.69 | TBXAS1 (0.41) | TBXAS1NPC1RAB9AHTTMAPK1 | |
| SCHEMBL6114927 | 0.67 | TBXAS1 (0.47) | TBXAS1TLR8NPC1RAB9AHTT | |
| SCHEMBL11440961 | 0.67 | TBXAS1 (0.47) | TBXAS1TLR8NPC1RAB9AHTT | |
| SCHEMBL6114991 | 0.67 | TBXAS1 (0.47) | TBXAS1TLR8NPC1RAB9AHTT | |
| SCHEMBL6114640 | 0.67 | TBXAS1 (0.47) | TBXAS1TLR8NPC1RAB9AHTT | |
| SCHEMBL11438392 | 0.67 | TBXAS1 (0.47) | TBXAS1TLR8NPC1RAB9AHTT | |
| SCHEMBL6114716 | 0.67 | TBXAS1 (0.47) | TBXAS1TLR8NPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2450985-B1 | ELECTRODE FOR SECONDARY BATTERY, SLURRY FOR SECONDARY BATTERY ELECTRODE, AND SECONDARY BATTERY | ZEON CORP (JP) | 2017-09-27 | — | — | EP | disclosed |
| US-9098001-B2 | Surface-modified metal oxide powder and process for producing same | NIPPON AEROSIL CO., LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-8877376-B2 | Electrode for secondary battery, slurry for secondary battery electrode, and secondary battery | ZEON CORPORATION (JP) | 2014-11-04 | — | — | US | disclosed |
| US-8841024-B2 | — | — | 2014-09-23 | — | — | US | disclosed |
| EP-2450985-A1 | ELECTRODE FOR SECONDARY BATTERY, SLURRY FOR SECONDARY BATTERY ELECTRODE, AND SECONDARY BATTERY | Zeon Corporation (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-20120107690-A1 | ELECTRODE FOR SECONDARY BATTERY, SLURRY FOR SECONDARY BATTERY ELECTRODE, AND SECONDARY BATTERY | ZEON CORPORATION (JP) | 2012-05-03 | — | — | US | disclosed |
| US-20120085978-A1 | SURFACE-MODIFIED METAL OXIDE POWDER AND PROCESS FOR PRODUCING SAME | NIPPON AEROSIL CO., LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
| EP-2236566-A1 | Water-insoluble colorant dispersion | Fujifilm Corporation (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100247878-A1 | WATER-INSOLUBLE COLORANT DISPERSION | FUJIFILM CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| CN-100384825-C | Benzheterocyclic derivatives | OTSUKA PHARMA CO LTD (JP) | 2008-04-30 | — | — | CN | disclosed |
| US-5670526-A | ANTIINFLAMMATORY AGENT, IMMUNOSUPPRESSANT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-23 | — | — | US | disclosed |
| CN-1158129-A | Novel benzimidazole derivatives having CGMP-phosphodisterase inhibiting activity | OTSUKA PHARMA CO LTD (JP) | 1997-08-27 | — | — | CN | disclosed |
| CN-1150799-A | Benzoheterocyclic derivatives | OTSUKA PHARMA CO LTD (JP) | 1997-05-28 | — | — | CN | disclosed |
| EP-0468470-B1 | Benzimidazoles, medicaments containing them and process for their preparation | THOMAE GMBH DR K (DE) | 1997-04-16 | — | — | EP | disclosed |
| EP-0765314-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-02 | — | — | EP | disclosed |
| WO-1997003070-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODISTERASE INHIBITING ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-30 | — | — | WO | disclosed |
| US-5587393-A | ANGIOTENSIN ANTAGONIST USEFUL IN TREATING HYPERTENSION | DR. KARL THOMAE GMBH (DE) | 1996-12-24 | — | — | US | disclosed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | disclosed |
| US-5385925-A | Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them | DR. KARL THOMAE GMBH (DE) | 1995-01-31 | — | — | US | disclosed |
| EP-0468470-A1 | Benzimidazoles, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120085978-A1 | SURFACE-MODIFIED METAL OXIDE POWDER AND PROCESS FOR PRODUCING SAME | TFRC, ITGA4, FEM1B | TBXAS1 4252/4885TLR8 4418/4885NPC1 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.